Search

Displaying results 1101 - 1110 of 9314 in total
  1. Drug

    Lopinavir

    go.drugbank.com/drugs/DB01601
    ApprovedInvestigational

    cannot be cleaved, thus preventing the activity of the HIV-1 protease. … [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's

    Mixtures: LOPINAVIR E RITONAVIR MYLAN, LOPINAVIR E RITONAVIR MYLANCategories: Antivirals used in combination for the treatment of HIV infections
  2. Drug

    Human varicella-zoster immune globulin

    go.drugbank.com/drugs/DB11621
    ApprovedInvestigational

    The therapeutic efficacy is proven if administered within 4 days of exposure to varicella zoster virus. … It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the disease severity in high-risk patients who

  3. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.

  4. Drug

    Evolocumab

    go.drugbank.com/drugs/DB09303
    ApprovedInvestigational

    Evolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … Evolocumab is the second PCSK9 inhibitor on the market, first being alirocumab.

  5. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same … -naive patients with NSCLC has been reported to be 1.4% - 21%.

  6. Drug

    Pyrimethamine

    go.drugbank.com/drugs/DB00205
    ApprovedInvestigationalVet approved

    One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

  7. Drug

    Benzydamine

    go.drugbank.com/drugs/DB09084
    ApprovedInvestigational

    Moreover, unlike aspirin-like NSAIDs which are acids or metabolised to acids, benzydamine is in fact a weak base. … It is used topically for pain relief and anti-inflammatory treatment of the mouth, throat, or muscoskeletal system.

    Mixtures: TANTUM VERDE GENGIVITE E STOMATITE, TANTUM VERDE GENGIVITE E STOMATITE
  8. Drug

    Ketoprofen

    go.drugbank.com/drugs/DB01009
    ApprovedInvestigationalVet approved

    Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.

    Mixtures: DOLFORT-DEProducts: Orudis E-50, Ketoprofen-E
  9. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells … It is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022].

  10. Drug

    Somatostatin

    go.drugbank.com/drugs/DB09099
    ApprovedInvestigationalWithdrawn

    It is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … hormones from the anterior pituitary [T28].

    Products: İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 FLAKON + 1 ÇÖZÜCÜ AMPUL